Citrullinated histone H3, a biomarker of neutrophil extracellular trap formation, predicts the risk of venous thromboembolism in cancer patients

Journal of Thrombosis and Haemostasis

Volumn 16, Issue 3, 2018, Pages 508-518

  Mauracher, L M ^a   Posch, F ^a,b   Martinod, K ^c   Grilz, E ^a   Daullary T ^a   Hell, L ^a   Brostjan, C ^a   Zielinski, C ^a   Ay, C ^a   Wagner, D D ^c   Pabinger, I ^a   Thaler, J ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

^c BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

cancer; H3Cit; neutrophil extracellular traps; thrombosis; venous thromboembolism

Indexed keywords

CIRCULATING TUMOR DNA; CITRULLINATED HISTONE H3; D DIMER; HISTONE H3; PADGEM PROTEIN; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; CITRULLINE; FIBRIN DEGRADATION PRODUCT; FIBRIN FRAGMENT D; HISTONE;

ADULT; AGED; ALL CAUSE MORTALITY; ARTICLE; CANCER PATIENT; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; LIMIT OF DETECTION; LOWER EXTREMITY DEEP VEIN THROMBOSIS; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; NEUTROPHIL COUNT; NUCLEOSOME; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; RISK FACTOR; UPPER EXTREMITY DEEP VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM; AUSTRIA; BLOOD CLOTTING; CANCER STAGING; CHEMISTRY; COMPLICATION; CYTOLOGY; DISEASE EXACERBATION; EXTRACELLULAR TRAP; METABOLISM; MIDDLE AGED; NEOPLASM; NEUTROPHIL; PROPORTIONAL HAZARDS MODEL; REMISSION; RISK; SOLUBILITY; VEIN THROMBOSIS;

AGED; AUSTRIA; BIOMARKERS; BLOOD COAGULATION; CITRULLINE; DISEASE PROGRESSION; EXTRACELLULAR TRAPS; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HISTONES; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS; NEUTROPHILS; NUCLEOSOMES; P-SELECTIN; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; REMISSION INDUCTION; RISK; SOLUBILITY; VENOUS THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 85041670042     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.13951     Document Type: Article

References (49)

1. Brinkmann V, Reichard U, Goosmann C, Fauler B, Uhlemann Y, Weiss DS, Weinrauch Y, Zychlinsky A. Neutrophil extracellular traps kill bacteria. Science 2004; 303: 1532–5.
2. Martinod K, Wagner DD. Thrombosis: tangled up in NETs. Blood 2014; 123: 2768–76.
3. von Bruhl ML, Stark K, Steinhart A, Chandraratne S, Konrad I, Lorenz M, Khandoga A, Tirniceriu A, Coletti R, Kollnberger M, Byrne RA, Laitinen I, Walch A, Brill A, Pfeiler S, Manukyan D, Braun S, Lange P, Riegger J, Ware J, et al. Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo. J Exp Med 2012; 209: 819–35.
4. Carestia A, Rivadeneyra L, Romaniuk MA, Fondevila C, Negrotto S, Schattner M. Functional responses and molecular mechanisms involved in histone-mediated platelet activation. Thromb Haemost 2013; 110: 1035–45.
5. Fuchs TA, Brill A, Duerschmied D, Schatzberg D, Monestier M, Myers DD Jr, Wrobleski SK, Wakefield TW, Hartwig JH, Wagner DD. Extracellular DNA traps promote thrombosis. Proc Natl Acad Sci USA 2010; 107: 15880–5.
6. Massberg S, Grahl L, von Bruehl ML, Manukyan D, Pfeiler S, Goosmann C, Brinkmann V, Lorenz M, Bidzhekov K, Khandagale AB, Konrad I, Kennerknecht E, Reges K, Holdenrieder S, Braun S, Reinhardt C, Spannagl M, Preissner KT, Engelmann B. Reciprocal coupling of coagulation and innate immunity via neutrophil serine proteases. Nat Med 2010; 16: 887–96.
7. Brill A, Fuchs TA, Savchenko AS, Thomas GM, Martinod K, De Meyer SF, Bhandari AA, Wagner DD. Neutrophil extracellular traps promote deep vein thrombosis in mice. J Thromb Haemost 2012; 10: 136–44.
8. Ay C, Pabinger I, Cohen AT. Cancer-associated venous thromboembolism: burden, mechanisms, and management. Thromb Haemost 2017; 117: 219–30.
9. Falanga A, Marchetti M, Russo L. The mechanisms of cancer-associated thrombosis. Thromb Res 2015; 135(Suppl. 1): S8–11.
10. Khorana AA. Cancer-associated thrombosis: updates and controversies. Hematology Am Soc Hematol Educ Program 2012; 2012: 626–30.
11. Demers M, Krause DS, Schatzberg D, Martinod K, Voorhees JR, Fuchs TA, Scadden DT, Wagner DD. Cancers predispose neutrophils to release extracellular DNA traps that contribute to cancer-associated thrombosis. Proc Natl Acad Sci USA 2012; 109: 13076–81.
12. Thalin C, Demers M, Blomgren B, Wong SL, von Arbin M, von Heijne A, Laska AC, Wallen H, Wagner DD, Aspberg S. NETosis promotes cancer-associated arterial microthrombosis presenting as ischemic stroke with troponin elevation. Thromb Res 2016; 139: 56–64.
13. Kessenbrock K, Krumbholz M, Schonermarck U, Back W, Gross WL, Werb Z, Grone HJ, Brinkmann V, Jenne DE. Netting neutrophils in autoimmune small-vessel vasculitis. Nat Med 2009; 15: 623–5.
14. Pabinger I, Thaler J, Ay C. Biomarkers for prediction of venous thromboembolism in cancer. Blood 2013; 122: 2011–18.
15. Posch F, Thaler J, Zlabinger GJ, Konigsbrugge O, Koder S, Zielinski C, Pabinger I, Ay C. Soluble vascular endothelial growth factor (sVEGF) and the risk of venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study (CATS). Clin Cancer Res 2016; 22: 200–6.
16. Konigsbrugge O, Posch F, Riedl J, Reitter EM, Zielinski C, Pabinger I, Ay C. Association between decreased serum albumin with risk of venous thromboembolism and mortality in cancer patients. Oncologist 2016; 21: 252–7.
17. Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials 1996; 17: 343–6.
18. Coviello V, Bogges M. Cumulative incidence estimation in the presence of competing risks. Stata J 2004; 4: 103–12.
19. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Statistics 1988; 16: 1141–54.
20. Fine JP, Gray RJA. Proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999; 94: 496–509.
21. Ay C, Posch F, Kaider A, Zielinski C, Pabinger I. Estimating risk of venous thromboembolism in patients with cancer in the presence of competing mortality. J Thromb Haemost 2015; 13: 390–7.
22. Lambert PC, Royston P. Flexible Parametric Alternatives to the Cox Model. UK Stata User Group 2009, 2009.
23. Lamber P. STCRPREP: Stata module to prepare data for competing risks analysis using time-dependent weights. https://ideas.repec.org/c/boc/bocode/s458015.html.
24. Ay C, Dunkler D, Marosi C, Chiriac AL, Vormittag R, Simanek R, Quehenberger P, Zielinski C, Pabinger I. Prediction of venous thromboembolism in cancer patients. Blood 2010; 116: 5377–82.
25. Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008; 111: 4902–7.
26. Connolly GC, Khorana AA, Kuderer NM, Culakova E, Francis CW, Lyman GH. Leukocytosis, thrombosis and early mortality in cancer patients initiating chemotherapy. Thromb Res 2010; 126: 113–18.
27. Martinod K, Demers M, Fuchs TA, Wong SL, Brill A, Gallant M, Hu J, Wang Y, Wagner DD. Neutrophil histone modification by peptidylarginine deiminase 4 is critical for deep vein thrombosis in mice. Proc Natl Acad Sci USA 2013; 110: 8674–9.
28. Martinod K, Fuchs TA, Zitomersky NL, Wong SL, Demers M, Gallant M, Wang Y, Wagner DD. PAD4-deficiency does not affect bacteremia in polymicrobial sepsis and ameliorates endotoxemic shock. Blood 2015; 125: 1948–56.
29. Li P, Li M, Lindberg MR, Kennett MJ, Xiong N, Wang Y. PAD4 is essential for antibacterial innate immunity mediated by neutrophil extracellular traps. J Exp Med 2010; 207: 1853–62.
30. Meng H, Yalavarthi S, Kanthi Y, Mazza LF, Elfline MA, Luke CE, Pinsky DJ, Henke PK, Knight JS. In vivo role of neutrophil extracellular traps in antiphospholipid antibody-mediated venous thrombosis. Arthritis Rheumatol 2017; 69: 655–67.
31. Wang Y, Li M, Stadler S, Correll S, Li P, Wang D, Hayama R, Leonelli L, Han H, Grigoryev SA, Allis CD, Coonrod SA. Histone hypercitrullination mediates chromatin decondensation and neutrophil extracellular trap formation. J Cell Biol 2009; 184: 205–13.
32. Fuchs TA, Kremer Hovinga JA, Schatzberg D, Wagner DD, Lammle B. Circulating DNA and myeloperoxidase indicate disease activity in patients with thrombotic microangiopathies. Blood 2012; 120: 1157–64.
33. van Montfoort ML, Stephan F, Lauw MN, Hutten BA, Van Mierlo GJ, Solati S, Middeldorp S, Meijers JC, Zeerleder S. Circulating nucleosomes and neutrophil activation as risk factors for deep vein thrombosis. Arterioscler Thromb Vasc Biol 2013; 33: 147–51.
34. Ording AG, Horvath-Puho E, Lash TL, Ehrenstein V, Borre M, Vyberg M, Sorensen HT. Prostate cancer, comorbidity, and the risk of venous thromboembolism: a cohort study of 44,035 Danish prostate cancer patients, 1995–2011. Cancer 2015; 121: 3692–9.
35. Kholia S, Jorfi S, Thompson PR, Causey CP, Nicholas AP, Inal JM, Lange S. A novel role for peptidylarginine deiminases in microvesicle release reveals therapeutic potential of PAD inhibition in sensitizing prostate cancer cells to chemotherapy. J Extracell Vesicles 2015; 4: 26192.
36. Thaler J, Ay C, Pabinger I. Venous thromboembolism in cancer patients – risk scores and recent randomised controlled trials. Thromb Haemost 2012; 108: 1042–8.
37. Riedl J, Preusser M, Nazari PM, Posch F, Panzer S, Marosi C, Birner P, Thaler J, Brostjan C, Lotsch D, Berger W, Hainfellner JA, Pabinger I, Ay C. Podoplanin expression in primary brain tumors induces platelet aggregation and increases risk of venous thromboembolism. Blood 2017; 129: 1831–9.
38. Noubouossie DF, Whelihan MF, Yu YB, Sparkenbaugh E, Pawlinski R, Monroe DM, Key NS. In vitro activation of coagulation by human neutrophil DNA and histone proteins but not neutrophil extracellular traps. Blood 2017; 129: 1021–9.
39. Schulz C, Massberg S. Demystifying the prothrombotic role of NETs. Blood 2017; 129: 925–6.
40. Holdenrieder S, Nagel D, Schalhorn A, Heinemann V, Wilkowski R, von Pawel J, Raith H, Feldmann K, Kremer AE, Muller S, Geiger S, Hamann GF, Seidel D, Stieber P. Clinical relevance of circulating nucleosomes in cancer. Ann N Y Acad Sci 2008; 1137: 180–9.
41. Schwarzenbach H, Hoon DS, Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer 2011; 11: 426–37.
42. Kerr JF, Winterford CM, Harmon BV. Apoptosis. Its significance in cancer and cancer therapy. Cancer 1994; 73: 2013–26.
43. Giacona MB, Ruben GC, Iczkowski KA, Roos TB, Porter DM, Sorenson GD. Cell-free DNA in human blood plasma: length measurements in patients with pancreatic cancer and healthy controls. Pancreas 1998; 17: 89–97.
44. Rumore PM, Steinman CR. Endogenous circulating DNA in systemic lupus erythematosus. Occurrence as multimeric complexes bound to histone. J Clin Invest 1990; 86: 69–74.
45. Khorana AA, Carrier M, Garcia DA, Lee AY. Guidance for the prevention and treatment of cancer-associated venous thromboembolism. J Thromb Thrombolysis 2016; 41: 81–91.
46. Mangold A, Alias S, Scherz T, Hofbauer T, Jakowitsch J, Panzenbock A, Simon D, Laimer D, Bangert C, Kammerlander A, Mascherbauer J, Winter MP, Distelmaier K, Adlbrecht C, Preissner KT, Lang IM. Coronary neutrophil extracellular trap burden and deoxyribonuclease activity in ST-elevation acute coronary syndrome are predictors of ST-segment resolution and infarct size. Circ Res 2015; 116: 1182–92.
47. Lewis HD, Liddle J, Coote JE, Atkinson SJ, Barker MD, Bax BD, Bicker KL, Bingham RP, Campbell M, Chen YH, Chung CW, Craggs PD, Davis RP, Eberhard D, Joberty G, Lind KE, Locke K, Maller C, Martinod K, Patten C, et al. Inhibition of PAD4 activity is sufficient to disrupt mouse and human NET formation. Nat Chem Biol 2015; 11: 189–91.
48. Brinkmann V, Goosmann C, Kuhn LI, Zychlinsky A. Automatic quantification of in vitro NET formation. Front Immunol 2012; 3: 413.
49. Vorobjeva NV, Pinegin BV. Neutrophil extracellular traps: mechanisms of formation and role in health and disease. Biochemistry (Mosc) 2014; 79: 1286–96.